IMUX
Immunic, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
16.80
▲ 0.70 (4.35%)
MARKET · —
Price
Open
16.08
Prev close
16.10
Day high
16.82
Day low
16.20
Volume
147.67K
Market cap
—
P/E (TTM)
—
52W range
5.06 – 17.43
Trailing performance
Returnvs SPY
1W
+2.74%
+4.1%
1M
+15.55%
+11.8%
3M
+34.15%
+31.0%
6M
+75.53%
+64.5%
YTD
+208.99%
+196.7%
1Y
+79.35%
+59.3%
3Y
0.00%
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
16.01
+4.91% from price
SMA 20
14.96
+10.26% from price
SMA 50
14.79
+11.53% from price
SMA 100
13.27
+26.62% from price
SMA 200
10.63
+55.16% from price
EMA 12
15.83
+6.14% from price
EMA 26
15.25
+10.19% from price
EMA 50
14.63
+14.84% from price
RSI (14)
61.8
Neutral
MACD (12,26,9)
0.58
Hist 0.17
ATR (14)
1.09
6.60% of price
Realised vol 30D
53.7%
Annualised
Bollinger upper
17.38
20, 2σ
Bollinger lower
12.55
20, 2σ
50 / 200 cross
Golden
14.79 vs 10.63
Trend bias
Above 200
+55.16%
Risk profile
Beta vs SPY
1.55
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
53.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-47.9%
Peak to trough
Max drawdown 5Y
-96.4%
Peak to trough
ATR 14
1.09
6.60% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
Zacks · 9d ago
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
Proactive · 11d ago
Immunic: Q2 Earnings Snapshot
Associated Press · 11d ago
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire · 11d ago
Immunic appoints Elena Ridloff to board of directors
Proactive · 12d ago
Immunic CEO on Q2 progress and Phase 3 MS trial milestones
Proactive · 12d ago
Immunic to Participate in Investor Conferences in July
PR Newswire · 44d ago
Immunic to Participate in Investor, Industry and Scientific Conferences in June
PR Newswire · 73d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.